Tenoxicam及Piroxicam治療退化性關節炎的比較性評估

A Comparative Evaluation of Tenoxicam and Piroxicam in the Treatment of Osteoarthritis

在本開放隨機性的比較研究中，39位退化性關節炎病人分別以每天20mg Tenoxicam（20例）及每天兩次10mg Piroxicam（19例）治療4週。兩組病人在主觀症狀如休息之關節疼痛及活動時之關節疼痛以及客觀症狀如關節壓痛與關節活動度上皆有顯著改善。病人之整體評估，在治療前均為“劣”或“可”，但在治療後，Tenoxicam組中有60％病人，Piroxicam組中有53％病人改善為“優”或“良”。兩組中各有一名病人發生腸胃副作用，Piroxicam組中有一例發生皮膚疹及臉部血管性水腫而停藥。並沒有發生系統性不良反應者，實驗室檢查數據在治療前後亦無改變。我們結論口服Tenoxicam每天20mg，對退化性關節炎是一有效且安全的治療。

In this open randomized comparative study, thirty-nine patients suffering from osteoarthritis were treated for four weeks with tenoxicam (TLC) 20 mg once daily (20 cases) or a comparative drug piroxicam (PRC) 10 mg twice daily (19 cases). Significant improvement was noted in both groups in terms of decreased joint pain at rest and pain on motion subjectively as well as objectively in terms of decreased joint tenderness and mobility limitation. The global assessment, poor or fair in all patients before treatment, turned out to be good or very good at the end of the study in 60% patients of the TLC group and 53% patients of the PRC group, respectively. One patient in each group developed gastrointestinal upset. One patient in the PRC group developed face angioedema and skin rash which led to withdrawal of therapy. No systemic adverse reactions were observed and the laboratory parameters showed no change. It is concluded that oral TLC 20 mg once daily is effective and safe for the treatment of patients suffering from osteoarthritis.